BR112022026265A2 - Métodos e composições para tratar hemofilia - Google Patents

Métodos e composições para tratar hemofilia

Info

Publication number
BR112022026265A2
BR112022026265A2 BR112022026265A BR112022026265A BR112022026265A2 BR 112022026265 A2 BR112022026265 A2 BR 112022026265A2 BR 112022026265 A BR112022026265 A BR 112022026265A BR 112022026265 A BR112022026265 A BR 112022026265A BR 112022026265 A2 BR112022026265 A2 BR 112022026265A2
Authority
BR
Brazil
Prior art keywords
compositions
methods
hemophilia
treat hemophilia
treat
Prior art date
Application number
BR112022026265A
Other languages
English (en)
Portuguese (pt)
Inventor
Mei Baisong
Andersson Shauna
Yu Qifeng
Dasmahapatra Pronabesh
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of BR112022026265A2 publication Critical patent/BR112022026265A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
BR112022026265A 2020-06-22 2021-06-22 Métodos e composições para tratar hemofilia BR112022026265A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063042390P 2020-06-22 2020-06-22
PCT/US2021/038445 WO2021262695A1 (en) 2020-06-22 2021-06-22 Methods and compositions for treating hemophilia

Publications (1)

Publication Number Publication Date
BR112022026265A2 true BR112022026265A2 (pt) 2023-01-17

Family

ID=76943130

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022026265A BR112022026265A2 (pt) 2020-06-22 2021-06-22 Métodos e composições para tratar hemofilia

Country Status (12)

Country Link
US (2) US20210393669A1 (cg-RX-API-DMAC7.html)
EP (1) EP4168018A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023531679A (cg-RX-API-DMAC7.html)
KR (1) KR20230027277A (cg-RX-API-DMAC7.html)
CN (3) CN115942940A (cg-RX-API-DMAC7.html)
AU (1) AU2021296786A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022026265A2 (cg-RX-API-DMAC7.html)
CA (1) CA3188137A1 (cg-RX-API-DMAC7.html)
IL (1) IL299295A (cg-RX-API-DMAC7.html)
MX (1) MX2023000164A (cg-RX-API-DMAC7.html)
TW (1) TW202216172A (cg-RX-API-DMAC7.html)
WO (1) WO2021262695A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240075001A1 (en) * 2022-05-24 2024-03-07 Darren Rubin Methods to reduce hemorrhage and mortality on the battlefield and applications for trauma patients
CA3258531A1 (en) * 2022-06-08 2023-12-14 Genzyme Corporation TREATMENT OF HEMOPHILIA WITH FITUSIRAN
CN118460655B (zh) * 2024-07-10 2025-01-28 凯莱英医药集团(天津)股份有限公司 抑制FXI基因表达的siRNA的制备方法
TW202610665A (zh) * 2024-07-10 2026-03-16 大陸商正大天晴藥業集團股份有限公司 靶向serpinc1的雙鏈核糖核酸

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9127274B2 (en) 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
IL308717A (en) 2015-12-07 2024-01-01 Genzyme Corp Methods and compositions for treating a serpinc1-associated disorder
JP2020530442A (ja) * 2017-07-10 2020-10-22 ジェンザイム・コーポレーション 血友病を有する対象の出血事象を処置するための方法および組成物

Also Published As

Publication number Publication date
TW202216172A (zh) 2022-05-01
EP4168018A1 (en) 2023-04-26
CN122124087A (zh) 2026-06-02
JP2023531679A (ja) 2023-07-25
IL299295A (en) 2023-02-01
CA3188137A1 (en) 2021-12-30
MX2023000164A (es) 2023-07-06
US20260014188A1 (en) 2026-01-15
WO2021262695A1 (en) 2021-12-30
CN122005597A (zh) 2026-05-12
CN115942940A (zh) 2023-04-07
KR20230027277A (ko) 2023-02-27
AU2021296786A1 (en) 2023-02-23
US20210393669A1 (en) 2021-12-23

Similar Documents

Publication Publication Date Title
MX2023000164A (es) Métodos y composiciones para tratar la hemofilia.
BR112022019932A2 (pt) Composições para saúde metabólica
BR112020017090A8 (pt) Imunoterapias relacionadas com microbioma
BRPI0909037B8 (pt) compostos moduladores da atividade de tlr, e composição farmacêutica
MX2022012780A (es) Inhibidores de homologo de oncogen viral de sarcoma de rata kirsten (kras) triciclicos fusionados.
BRPI0808746B8 (pt) derivado de purinila como modulador do canal de potássio, composição farmacêutica, e, uso de um derivado de purinila.
BR112015013105A2 (pt) composições de irna de pcsk9 e métodos de uso das mesmas
MX2009010122A (es) Derivados de purinilo y su uso como moduladores del canal de potasio.
BR112016029041A8 (pt) uso de um inibidor de glutaminase, composição farmacêutica e kit farmacêutico
JOP20230157A1 (ar) طرق مُعالجة فيروس كورونا
BR112016004095A2 (pt) administração de enzimas de empobrecimento de quinurenina para a terapia contra tumores
BR112022004397A2 (pt) Composições para tratamento bucal que compreendem beta ácidos de lúpulo e aminoácidos
CL2021000924A1 (es) Uso de reboxetina para el tratamiento de narcolepsia
MX2022014925A (es) Moduladores de il-17a.
CO2025013790A2 (es) Compuestos heterocíclicos como inhibidores de wrn
CO2022016754A2 (es) Moléculas de fijación para el tratamiento de cáncer
CO2017008765A2 (es) Nueva triterpenona c-3 con derivados de amida inversa c-17 como inhibidores de vih
CY1120906T1 (el) Συνθεσεις οξπρενολολης για τη θεραπεια του καρκινου
CL2011002160A1 (es) Compuestos derivados de 3-amino-2-mercaptoquinolinas sustituidas; composicion farmaceutica que contiene dichos compuestos; y su uso para tratar dolor, epilepsis, incontinencia urinaria, manias, migraña, trastornos bipolares, enfermedades cognitivas, discinesia asociada a la distonia y/o incontinencia urinaria.
BR112014000634A2 (pt) métodos para tratamento de incontinência associada com atividade sexual
ES2380951T3 (es) Diaril-purinas, -azapurinasy - desazapurinas como inhibidores no nucleósidos de la transcriptasa inversa para el tratamiento del VIH
BR112022024754A2 (pt) Composições e métodos para tratar covid longo
WO2020049552A9 (en) Tissue repair by activated cells
MX2021009443A (es) Composiciones que contienen bacterias productoras de bacillaeno o preparaciones de las mismas.
AR131101A1 (es) Heteroarilfluoroalquenos como inhibidores de dgk